跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 387 条关于
“ESR2”
全部
387
临床试验
352
药物
8
机构
0
资讯
27
9个月前
Large-Scale Drug Screen Reveals Common Medicines Can Enhance CRISPR Therapy and Target DNA Repair-Deficient Cancers
3年前
ASCO Updates Guidelines: ESR1 Mutation Testing Recommended for Advanced Breast Cancer
去年
ESR1 Mutations in Breast Cancer: Emerging Biomarker Reshapes Treatment Strategies
去年
Elacestrant Demonstrates Efficacy in ESR1-Mutated, Endocrine-Sensitive Breast Cancer
去年
ESR1 Mutation Testing Gains Importance in HR-Positive Breast Cancer Treatment
4个月前
FDA Approves First PROTAC Drug VEPPANU for ESR1-Mutated Breast Cancer
去年
Real-World Data Suggests Elacestrant Offers Similar or Improved Outcomes in Advanced Breast Cancer
去年
NHS Rejects Elacestrant (Korserdu) for Advanced Breast Cancer with ESR1 Mutation
去年
SeaStar Medical's SCD Receives FDA Breakthrough Device Designation for ESRD Treatment
去年
SeaStar Medical's Selective Cytopheretic Device Receives FDA Breakthrough Designation for ESRD Inflammation
第 1 页,共 3 页
上一页
下一页